ERBB2 and triple-negative breast carcinoma: VYBC has aggressive clinical and pathological features and is more likely to develop tumors of a larger size, have higher lymph node positivity rates, present with more advanced stages, have increased lymphovascular invasion, have higher histological grades, have lower hormone receptor positivity rates, have overexpression of the human epidermal growth factor receptor 2 (HER2), and have a higher proportion of triple-negative breast cancer (TNBC) [5, 6, 13].